Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study

Autor: Pierre Mongiat-Artus, Tristan Delory, Jean-Michel Molina, Anthony Laurancon-Fretar, Alexandra Masson-Lecomte, Annabelle Goujon, Matthieu Lafaurie, Béatrice Berçot, Pauline Arias
Přispěvatelé: Service de maladies infectieuses et tropicales [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'Urologie [CHU Saint-Louis], Service de microbiologie [Saint-Louis], Gestionnaire, Hal Sorbonne Université, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris (UP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Microbiology (medical)
Prostatic Diseases
medicine.medical_specialty
Prostate biopsy
Biopsy
[SDV]Life Sciences [q-bio]
030106 microbiology
Fosfomycin
Logistic regression
urologic and male genital diseases
lcsh:Infectious and parasitic diseases
03 medical and health sciences
0302 clinical medicine
Prostate Biopsy
Internal medicine
medicine
Humans
lcsh:RC109-216
Prospective Studies
030212 general & internal medicine
Tromethamine
Adverse effect
Prospective cohort study
Ultrasonography
Interventional
Aged
medicine.diagnostic_test
business.industry
Prophylaxis
Incidence (epidemiology)
Prostate
General Medicine
Antibiotic Prophylaxis
Middle Aged
Ultrasound-Guided Prostate Biopsy
Anti-Bacterial Agents
3. Good health
[SDV] Life Sciences [q-bio]
Infectious Diseases
business
Cohort study
medicine.drug
Fluoroquinolones
Zdroj: International Journal of Infectious Diseases, Vol 102, Iss, Pp 269-274 (2021)
International Journal of Infectious Diseases
International Journal of Infectious Diseases, Elsevier, 2021, 102, pp.269-274. ⟨10.1016/j.ijid.2020.10.065⟩
ISSN: 1201-9712
1878-3511
DOI: 10.1016/j.ijid.2020.10.065⟩
Popis: International audience; Objectives: The increasing incidence of fluoroquinolones (FQ) resistance may lower its efficacy in preventing UTI following transrectal ultrasound-guided prostate biopsy (TRUS-PB). We assessed the efficacy and safety of FQ and fosfomycin-trometamol (FT) in patients undergoing TRUS-PB.Methods: A prospective observational study was conducted between April 2017 and June 2019 and enrolled men undergoing TRUS-PB and receiving a single-dose of FQ (FQ-arm) or FT (FT-arm) for UTI prophylaxis per physician's choice. The primary efficacy endpoint was self-reported TRUS-PB UTI. We assessed baseline factors associated with UTI with logistic regression.Results: A total of 222 men were enrolled, 141/222 (64%) received FQ, and 81/222 (36%) FT. The median age was 67.6 years [IQR, 61.4-72.1] and the Charlson score was 3 [IQR, 3-5]. The overall incidence of self-reported TRUS-PB UTI was 12% (24/197, (95%CI, 8%-17%)): 15% (17/116, (95% CI, 10%-17%)) in FQ-arm, versus 9% (7/81, 95% CI (5%-13%)) in FT-arm (RR = 0.55 (95% CI, 0.22-1.40), p-value = 0.209). No baseline characteristic was significantly associated with TRUS-PB UTI. Safety was similar between the arms: the rate of the reported adverse event was 31% (36/116, (95% CI, 25%-37%) in the FQ-arm versus 36% (28/81, (95% CI, 28%-41%)) in the FT-arm (RR = 1.17 (95% CI, 0.64-2.15), p = 0.602).Conclusions: TRUS-PB UTI prophylaxis with FT and FQ has similar efficacy and safety. A randomized comparison of these two antibiotics is warranted.
Databáze: OpenAIRE
Externí odkaz: